Nicola Bonner clarifies the guidelines, and which are relevant, to ensure practitioners maintain high and consistent standards. Published on Pharmaphorum 26th June 2015 Qualitative and quantitative non-interventional health outcomes research studies are on the increase, but there are misconceptions about where this relatively new field… Read More
Thought Leadership
“Knowledge has to be improved, challenged, and increased constantly, or it vanishes.”
Peter Drucker
Adelphi Values offer a unique blend of strategic and technical knowledge, expertly applied to demonstrate and communicate the real value of healthcare.
Bruce Charlesworth writes for Pharmaphorum about how in today’s value-based healthcare environment, it’s important to take an integrated, multi-perspective approach to value demonstration. Bruce starts the article by considering what the following have in common: The choice to advance or kill a molecule in development, a split-second prescribing preference, the… Read More
Rob Arbuckle from Adelphi Values and Linda Abetz-Webb publish in The Patient – a journal focused on Patient-Centered Outcomes Research. The US FDA and the European Medicines Agency (EMA) have issued incentives and laws mandating clinical research in pediatrics. While guidance for the development and validation of patient-reported outcomes (PROs)… Read More
At Adelphi Values PROVE we recognise that value demonstration for orphan/ ultra-orphan drugs in rare diseases requires a different focus to support successful market access. Read More
Linda Abetz-Webb from Adelphi Values (formerly named Mapi Values) writes for Pharmaphorum about how many treatments with potential value in children have not been tested in paediatric populations. Incentives and penalties to encourage paediatric research are in place, but measuring disease symptoms and impact in children and infants can… Read More
Alan Shields, PhD from Adelphi Values collaborates with Erin Zagadailov, PharmD, MS and Michael Fine, MD to write for American Health & Drug Benefits – the peer-reviewed forum for real-world evidence in benefit design. Background: Because of the increasingly significant role of PROs in the development and evaluation of new… Read More
In an article published by Pharmaphorum, Sarah and Laura from Adelphi Values discuss how more and more people are becoming informal caregivers due to ageing populations and the increase in chronic medical conditions. They suggest that when new treatments are developed, this should be reflected by regulators taking into account… Read More
Bruce Charlesworth from Adelphi Values (formerly named Mapi Values) writes for Pharmaphorum about the opportunity surrounding defining value in healthcare, and how it has evolved from traditional efficacy or tolerability. Read More